Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: OTHER: Laboratory Biomarker Analysis|DRUG: Tivantinib
Sponsor: National Cancer Institute (NCI)